BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23% For WtKRAS
BioAtla 在 IASLC 2024 上展示了有關突變 KRAS 基因型和接受 Mecbotamab Vedotin（一種 CAb-AXL-ADC）治療的晚期 NSCLC 患者臨床結果的數據；對於表達 MKRAS 的 NSCLC 患者，1 年的生存率爲 58%，而 WtKRAS 的患者爲 23%。
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
與接受 Mec-V 治療的野生型 KRAS (wtKRAS) 治療無反應的非小細胞肺癌患者相比，接受 Mec-V 治療的突變 KRAS (mKRAS) 患者的中位總體生存率 (OS) 得到了改善。
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
對於表達 mKRAS 的 NSCLC 患者，1 年的生存率爲 58%，而 wtKRAS 患者爲 23%。
Mec-V antitumor activity observed across 9 different mKRAS variants
Mec-V 在 9 種不同的 mKRAS 變體中觀察到了抗腫瘤活性。
Strong association of AXL expression by mKRAS NSCLC confirmed
mKRAS NSCLC AXL 表達的強相關性得到確認。
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster entitled "Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC" at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting on December 14, 2024.
加利福尼亞州聖地亞哥，2024 年 12 月 16 日（全球新聞通訊）-- BioAtla, Inc.（納斯達克：BCAB）是一家專注於開發有條件活性生物（CAB）抗體治療用於實體瘤治療的全球臨床階段生物技術公司，於 2024 年 12 月 14 日在 IASLC 2024 熱點基礎與轉化科學會議上展示了題爲 "突變 KRAS 基因型和接受 Mecbotamab Vedotin（一種 CAb-AXL-ADC）治療的晚期 NSCLC 患者臨床結果的特徵" 的海報。
譯文內容由第三人軟體翻譯。
